Rivoceranib (also known as apatinib), a novel oral small-molecule selective tyrosine kinase inhibitor of VEGFR2, blocks endothelial and tumour cell proliferation and migration, thus inhibiting tumour growth [13, 14]. This evidence concerns the gene KDR and neoplasm.